What is the primary reason for the compensation changes reported in this 8-K filing?

The primary reason for the compensation changes is to reflect the increased responsibilities of certain Boston Scientific executives, particularly within the Cardiac Rhythm Management (CRM) business, following the closing of the Guidant acquisition. Additionally, retention and recognition awards are being offered to key Guidant executives and Boston Scientific employees who were instrumental in the transaction.

What types of long-term incentives are being awarded to these executives?

The long-term incentive awards include stock options to purchase common stock, deferred stock unit awards for common stock, and in some cases, a cash component. These awards are designed to align executive interests with the company's performance and the success of the Guidant integration.

When will these stock options and deferred stock units begin to vest or be issued?

The stock options will vest in equal annual installments over four years, beginning on May 8, 2007. The deferred stock unit awards will be issued in four equal annual installments, beginning on May 8, 2008.

Are these compensation changes solely for Boston Scientific employees?

No, these compensation changes also include retention awards for key executives of Guidant Corporation and special recognition awards for certain Boston Scientific employees who contributed to the Guidant transaction.

BSX 8-K: Material Agreements

Summary

This Form 8-K filing by Boston Scientific Corporation (BSX) on May 12, 2006, primarily details significant compensation adjustments and award grants related to the recent acquisition of Guidant Corporation. The company has appointed two new members to its Executive Committee and has approved substantial salary increases, performance incentives, and long-term incentive awards for these individuals, as well as for Fred A. Colen, the Chief Technology Officer. These adjustments are tied to their increased responsibilities within the Cardiac Rhythm Management (CRM) business post-Guidant acquisition. Furthermore, the filing outlines retention awards for key Guidant executives and special recognition awards for Boston Scientific employees instrumental in the Guidant transaction. These awards, which include stock options, deferred stock units, and cash components, are designed to incentivize and retain talent during this critical integration period. The details of these compensation packages, including vesting schedules and award structures, are provided, emphasizing the company's efforts to manage its executive team and integrate the acquired business effectively.

Key Highlights

1Appointment of two new members to Boston Scientific's Executive Committee: Mark C. Bartell and William F. McConnell.
2Significant salary increases, performance incentive opportunities, and long-term incentive awards (stock options, deferred stock units, cash) granted to Messrs. Bartell, McConnell, and Fred A. Colen.
3These compensation adjustments are directly linked to increased responsibilities within the Cardiac Rhythm Management (CRM) business following the Guidant transaction.
4Approval of retention awards for key executives of Guidant Corporation to ensure continuity and retention post-acquisition.
5Special recognition awards, including cash, stock options, and deferred stock units, granted to certain Boston Scientific employees for their contributions to the Guidant transaction's success.
6All stock options and deferred stock unit awards are made under the Company’s 2003 Long-Term Incentive Plan with specific vesting and issuance schedules over four years, beginning in May 2007 for options and May 2008 for deferred units.
7The filing specifies the forms of incentive award agreements attached as exhibits, detailing the structure of these compensation packages.

BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (May 12, 2006)

Summary

Key Highlights

Frequently Asked Questions